

**Table 3.6 Selected clinical trials conducted on licensed antifungals**

Antifungal prophylaxis	Neutropenic fever	Invasive aspergillosis	Candidaemia or invasive candidiasis	Oesophageal candidiasis
Voriconazole vs. placebo (182)	Micafungin vs caspofungin (183)	<u>Posaconazole</u> vs liposomal amphotericin B ± caspofungin (184)	Caspofungin vs amphotericin B (172); <u>Caspofungin</u> vs amphotericin B in newborn infants (185)	Caspofungin vs amphotericin B (186–187)
Micafungin vs fluconazole (188); <u>Micafungin</u> vs fluconazole (189); Micafungin vs fluconazole, liposomal amphotericin B or caspofungin post-liver-transplant (190)	Caspofungin vs liposomal amphotericin B (191); <u>Caspofungin</u> vs liposomal amphotericin B (192)	<u>Voriconazole</u> vs amphotericin B (173,193)	Caspofungin (standard vs high dose) (194)	Caspofungin vs fluconazole (195)
<u>Itraconazole</u> vs fluconazole (196–197)	Voriconazole vs liposomal amphotericin B (198)	Liposomal amphotericin B (standard dose vs high loading dose) (199)	Anidulafungin vs fluconazole (200); Anidulafungin vs fluconazole in critically ill (201)	Anidulafungin vs fluconazole (202)
<u>Posaconazole</u> vs fluconazole or itraconazole (203–205)	Itraconazole vs amphotericin B (206–207)	Isavuconazole vs voriconazole (for invasive mould disease) (208)	Micafungin vs caspofungin (177)	Micafungin vs fluconazole (209–210)
<u>Voriconazole/ posaconazole</u> vs fluconazole/ itraconazole in AML/MDS undergoing chemotherapy (211); <u>Voriconazole</u> vs itraconazole in post allogeneic HSCT (212); Voriconazole vs fluconazole in post allogeneic HSCT (213)	Different amphotericin B formulations (214–215)	Voriconazole and anidulafungin vs voriconazole monotherapy (216)	Micafungin vs liposomal amphotericin B (217–219)	Voriconazole vs fluconazole (220)

Antifungal prophylaxis	Neutropenic fever	Invasive aspergillosis	Candidaemia or invasive candidiasis	Oesophageal candidiasis
<u>Aerosolized liposomal amphotericin B</u> vs placebo inhalation (221)	<u>Micafungin</u> vs itraconazole (222)		Voriconazole vs amphotericin B followed by fluconazole (223)	Isavuconazole vs fluconazole (224)
Voriconazole vs low dose amphotericin B in paediatric acute leukaemia induction (225)	Immediate voriconazole vs deferred placebo (226)		Micafungin vs voriconazole in kidney transplant recipients (227)	
Anidulafungin vs fluconazole in high-risk liver transplant patients (228)			Preemptive micafungin following gastrointestinal surgery (229)	
Caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis (230)			Caspofungin vs micafungin (231)	

Note:

AML, acute myelogenous leukaemia

HSCT, haematopoietic stem cell transplantation

MDS, myelodysplastic syndromes

Agent with superior results for some outcomes is underlined.